- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06351358
Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies
A Multi-center, Open-label Study to Evaluate the Synergistic Effects of Biostimulator and Dermal Fillers for Cheek Augmentation and Correction of Contour Deficiencies
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multi-center, open-label study. Subjects will be screened on the basis of the selection criteria for study qualification. Eligible subjects will have initial treatment of Sculptra and Restylane Lyft or Restylane Contour on both cheeks at the Baseline visit.
At Week 4, subjects will receive a second Sculptra treatment on both cheeks for optimal correction and an optional touch-up of Restylane Lyft or Restylane Contour for optimal correction, defined as at least a 1-grade improvement on the GCWS and MMVS.
At Week 8, subjects will receive an optional Sculptra treatment on both cheeks for optimal correction.
Subjects will have the last follow-up visit at Week 16 if the last Sculptra treatment is at Week 4 or at Week 20 if the last Sculptra treatment is at Week 8.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sindhu Garimella
- Phone Number: 2146909747
- Email: sindhu.garimella@galderma.com
Study Contact Backup
- Name: Thu Nguyen
- Email: Thu.Nguyen@galderma.com
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- Enrolling by invitation
- Somenek + Pittman MD: Advanced Plastic Surgery
-
-
New York
-
New York, New York, United States, 10028
- Recruiting
- Lorenc Aesthetic Plastic Surgery Center
-
Contact:
- Paul Lorenc, MD
- Phone Number: 212-472-2900
- Email: lorenc@lorenc.com
-
Contact:
- Allison Bonugli
- Email: allison@lorenc.com
-
Principal Investigator:
- Paul Z Lorenc, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any Fitzpatrick skin types I-VI, with effort to include minimum n = 1 for each category per site
- Any races and ethnicities, with effort to include minimum n = 2 per site for whom identify as American Indian or Alaska Native, Eastern/Southeastern Asian, South Asians, Hispanic or Latino, Black or African American, Native Hawaiian or Other Pacific Islander, etc.
- Subject with moderate-to-severe cheek wrinkles on the GCWS
- Subject with mild-to-severe midface contour deficiencies on the MMVS
- Subject with intent to undergo correction of cheek augmentation or midface contour deficiencies.
- Subject with history of taking or currently taking GLP-1 receptor agonist medications such as semaglutide, liraglutide, etc.
- Subject with stable Body Mass Index (BMI) within 4-6 weeks before study start.
- Subject willing to maintain a stable Body Mass Index (BMI, ± 2 kg/m2) throughout the study.
- Willing to maintain the current lifestyle and daily routine (e.g., diet, exercise, sleep, etc.) throughout the study.
- Subject willing to be photographed at each visit.
- Subject willing to abstain from any other facial plastic surgical or cosmetic procedure(s) during the duration of the study.
- For female subjects of childbearing potential, she agrees to use an acceptable form of effective birth control for the duration of the study. Subjects must be willing to take a urine pregnancy test (UPT) prior to all treatments. (Females of non-childbearing potential, e.g., post-menopausal (absence of menstrual bleeding for 1 year without any other medical reason), hysterectomy, or bilateral ovariectomy, are not required to have a UPT.)
- Male subjects must be willing to shave prior to each study visit.
- Ability to read, understand and give consent for participation in the study.
- Agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments.
Exclusion Criteria:
- Pregnant, breastfeeding, or planning pregnancy during the course of the study.
- Current smokers or consumer of nicotine.
- History of allergy or hypersensitivity to any ingredient of the treatment products, anesthetics or lidocaine
- Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions
- Previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except the lips
- History of injectable polymethylmethacrylate (PMMA) treatment
- Previous treatment/procedure in the face in the previous 6 months that, in the Investigator's opinion, would interfere with the study injections and/or study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures in the treatment area at any time during the study
- Presence of any disease or lesions near or on the area to be treated
- History of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation (e.g., aspirin or other non-steroidal anti-inflammatory drugs), omega 3, or vitamin E within 14 days before treatment. Omega 3 and vitamin E are acceptable only as part of a standard multivitamin formulation.
- Previous surgery, including plastic surgery, lifting threads, tissue grafting, or tissue augmentation with permanent implants, silicone, tattoo affecting the treatment area, or any procedure, at the discretion of the Investigator, would interfere with the outcome of the study.
- Any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion
- Other condition preventing the subject from entering the study in the Investigator's opinion
- Study site personnel, close relatives of the study site personnel (e.g., parents, children, siblings, or spouse), or employees and close relatives of employees at the Sponsor company.
- Participation in any interventional clinical study within 30 days of screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sculptra and Restylane Treatment Group
Subjects in the treatment group will receive the intervention with Sculptra and Restylane Lyft or Restylane Contour.
|
Subjects will receive treatment of Sculptra at baseline.
Subjects will receive a second treatment of Sculptra at Week 4 visit.
At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline.
Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in skin hydration from baseline
Time Frame: Baseline, Week 4, Week 8, Week 16 or Week 20
|
Corneometer (Courage + Khazaka, Germany) measurements will be taken in triplicate to assess skin hydration.
The Corneometer measures in Corneometer units from 0 (no water at all) - 120 (on water).The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth.
An increase in scores indicates an improvement.
|
Baseline, Week 4, Week 8, Week 16 or Week 20
|
Change in skin radiance from baseline
Time Frame: Baseline, Week 4, Week 8, Week 16 or Week 20
|
Glossymeter (Courage + Khazaka, Germany) measurements will be taken to assess skin radiance.
The results will be expressed in Glossymeter units.
The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth.
An increase in scores indicates an improvement.
|
Baseline, Week 4, Week 8, Week 16 or Week 20
|
Change in skin elasticity from baseline
Time Frame: Baseline, Week 4, Week 8, Week 16 or Week 20
|
Cutometer (Courage + Khazaka, Germany) measurements will be taken to assess skin elasticity.
The Cutometer measures skin elasticity in mm penetration depth per unit of time.
The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth.
An increase in scores indicates an improvement.
|
Baseline, Week 4, Week 8, Week 16 or Week 20
|
Change in skin thickness from baseline
Time Frame: Baseline, Week 4, Week 8, Week 16 or Week 20
|
DermaLab® Ultrasound (Cortex Technology, Denmark) measurements will be taken in triplicate to assess skin thickness in µm.
The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth.
An increase in scores indicates an improvement.
|
Baseline, Week 4, Week 8, Week 16 or Week 20
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Treatment Satisfaction
Time Frame: Week 4, Week 8, Week 16 or Week 20
|
Subjects will be asked about their perception and satisfaction with the study treatments using a self-assessment questionnaire at each visit after Baseline.
Questionnaires will be tabulated; and the frequency and percentage of all response options will be reported for each question and time point.
Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) will be tabulated and reported as appropriate.
|
Week 4, Week 8, Week 16 or Week 20
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Somenek, MD, Somenek + Pittman MD: Advanced Plastic Surgery
- Principal Investigator: Paul Z Lorenc, MD, Z. Paul Lorenc Aesthetic Plastic Surgery
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLI.04.US.SL.036
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Weight Loss
-
United States Army Research Institute of Environmental...USDA Grand Forks Human Nutrition Research Center; Eastern Michigan UniversityCompletedWeight Loss | Bone Loss | Muscle LossUnited States
-
Case Comprehensive Cancer CenterUniversity Hospitals Seidman Cancer CenterRecruitingUnintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking CombinUnintended Weight LossUnited States
-
Zhen Jun WangUnknownSleeve Gastrectomy | Excessive Weight Loss | Total Weight Loss | Jejunojejunal Bypass | UncutChina
-
HealthPartners InstituteNational Cancer Institute (NCI)Completed
-
Dana-Farber Cancer InstituteCompletedWeight Loss Program After Cancer DiagnosisUnited States
-
Medical University of ViennaCompleted
-
Power Life Sciences Inc.Not yet recruitingGastric Bypass | Weight Loss Surgery
-
University at BuffaloHarvard Medical School (HMS and HSDM)TerminatedWeight Loss | Appetite LossUnited States
-
Duke UniversityNational Institute on Aging (NIA)Suspended
-
Drexel UniversityUniversity of PennsylvaniaCompletedObesity | Overweight | Weight Loss MaintenanceUnited States
Clinical Trials on Sculptra treatment
-
Henry Ford Health SystemGalderma R&DCompletedStriae DistensaeUnited States
-
Galderma R&DActive, not recruitingMidface Volume DeficitChina
-
Goldman, Butterwick, Fitzpatrick and GroffGalderma R&DRecruiting
-
Dermatology Cosmetic Laser Medical Associates of...SanofiWithdrawnEmaciation | LipodystrophyUnited States
-
Galderma R&DCompleted
-
Galderma R&DCompletedCheek WrinklesUnited States
-
GCS Co., LtdEurofins Dermscan PharmascanActive, not recruiting
-
Galderma R&DCompletedWrinkles in DecolletageUnited States